Opinion|Videos|March 13, 2025
Lenvatinib and Depth of Response in Advanced uHCC: Insights From REFLECT
Author(s)Amit Mahipal, MD
An expert discusses how recent analyses from the REFLECT trial in unresectable hepatocellular carcinoma (uHCC) demonstrate that both achieving objective response and greater depth of response correlate with improved survival outcomes. The depth of response serves as a potentially valuable early biomarker for prognosis and treatment decisions, with deeper responses associated with better overall survival among responders.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What role do the overall response and depth of response play in guiding treatment decisions for advanced uHCC?
- Review recent evidence from REFLECT looking at characterization of tumor response.
- Please discuss the clinical implications from the best overall response, depth of response, and overall survival among responders’ data.
- What are your thoughts on looking at the depth of response as a marker for clinical outcomes?
Advertisement
Related to this article
The FDA assigned an April 9, 2027, PDUFA date to rivoceranib plus camrelizumab for first-line treatment of unresectable or metastatic hepatocellular carcinoma.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Pimicotinib for Symptomatic Tenosynovial Giant Cell Tumor
2
FDA Approves OncoMate MSI Dx For Pembrolizumab in MSI-H Tumors
3
Oncologists Discuss Ibrutinib Switching and Fixed-Duration Therapy in CLL
4
Novocure’s Optune Mya Gets FDA Not Approvable Letter
5